BMEA
Biomea Fusion, Inc.·Healthcare
1.87
1.081%(+0.02)
Market ClosedLast Updated: — ET
52W L: $0.8752W H: $3.08
Biomea Fusion, Inc.·Healthcare
Biomea Fusion, Inc. (NASDAQ: BMEA - Get Free Report) has been given a consensus rating of "Moderate Buy" by the nine ratings firms that are covering the company, Marketbeat reports. One investment analyst has rated the stock with a sell recommendation, seven have issued a buy recommendation and one has assigned a strong buy recommendation to
COVALENT-211 Phase II enrolling insulin-deficient type 2 diabetes patients COVALENT-212 Phase II enrolling type 2 diabetes patients uncontrolled with a GLP-1 receptor agonist-based therapy Topline 26-week primary endpoint data from both Phase II studies anticipated 4Q 2026
Biomea Fusion, Inc. (BMEA) Discusses Menin Inhibition Mechanism and Therapeutic Potential in Diabetes Transcript
Biomea Fusion, Inc. (BMEA) Discusses Phase I Data and Clinical Potential of Oral GLP-1 Receptor Antagonist for Obesity Transcript
SAN CARLOS, Calif., March 24, 2026 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea” or “Biomea Fusion” or “the Company”) (Nasdaq: BMEA), a clinical-stage diabetes and obesity company, today reported its financial results for the full year ended December 31, 2025, and provided a business update.
Biomea Fusion (NASDAQ: BMEA - Get Free Report) is anticipated to announce its Q4 2025 results before the market opens on Monday, March 30th. Analysts expect the company to announce earnings of ($0.25) per share for the quarter. Interested persons can find conference call details on the company's upcoming Q4 2025 earning report page for the